Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past three months, 14 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), with a mix of bullish and bearish opinions. The average 12-month price target is $1057.0, with a high of $1200.00 and a low of $720.00. Recent analyst actions include several rating raises and maintained ratings, reflecting varied perspectives on the company's future performance.
June 04, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals (NASDAQ:REGN) has received mixed analyst ratings over the past three months, with an average 12-month price target of $1057.0. Recent actions include several rating raises and maintained ratings, indicating varied perspectives on the company's future performance.
The mixed analyst ratings and recent actions, including several rating raises, suggest a generally positive outlook for Regeneron Pharmaceuticals. The average price target has slightly increased, indicating confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100